Mov­ing on past so­la wreck­age, Lil­ly dou­bles down on one more Alzheimer’s drug from As­traZeneca

Eli Lil­ly may be down to­day as a re­sult of the fi­nal read­out of the num­bers on solanezum­ab. But it’s not out.

The phar­ma gi­ant said to­day that it is part­ner­ing with As­traZeneca on a new amy­loid be­ta treat­ment for Alzheimer’s dubbed ME­DI1814. That drug tar­gets amy­loid be­ta 42, a com­ple­men­tary ap­proach to their pro­gram for the BACE drug AZD3293, which Lil­ly took di­rect con­trol of as As­traZeneca con­tin­ued its slow and steady ex­it from the CNS field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER